Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

Brief Summary

MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.

Intervention / Treatment

  • Drug: MDMA
  • Drug: Pindolol

Condition or Disease

  • Mood Disorder
  • Substance-Related Disorders
  • Amphetamine-Related Disorders

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 18 Years to 45 Years   (Adult)
Enrollment: 16 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Jun 01, 2001
Primary Completion: Mar 01, 2002
Completion Date: Mar 01, 2002
Study First Posted: May 08, 2009
Results First Posted: Aug 30, 2020
Last Updated: Jun 15, 2009

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

We investigated the interactive effects of the beta-blocker pindolol (20 mg) with MDMA (1.6 mg/kg) on heart rate, blood pressure, body temperature, and adverse effects in a double-blind placebo-controlled study in 16 healthy subjects.

Eligibility Criteria

Sex: Male
Minimum Age: 18
Maximum Age: 45

More Details

NCT Number: NCT00895804
Other IDs: E-003/2001
Study URL: https://ClinicalTrials.gov/show/NCT00895804
Last updated: Jun 17, 2022